Benefits
Specified pediatric growth disorders and adult growth-hormone deficiency; not general anti-aging treatment.
Named U.S. presentation only; selected label sections.
Peptide library
Somatropin (HGH)
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The named U.S. product label is the appropriate source for its approved use, contraindications and handling. GENOTROPIN: mean terminal half-life was about 0.4 hours after IV administration in normal adults and 3.0 hours after SC administration in adults with GH deficiency. Slower SC absorption explains the difference. Concentrations/formulations and patient populations are not interchangeable. A label extraction is not an independent appraisal of every supporting trial or approval of other products with the same ingredient.
About this assessment
Named U.S. product label sections assessed.
Product-specific editorial extraction. Complete clinical review and clinician sign-off remain pending; other jurisdictions are not inferred.
Editorial assessment · 2026-09-07
Who was studied
The population specified by this product label; other indications and jurisdictions remain outside this check.
What the sources found
Specified pediatric growth disorders and adult growth-hormone deficiency; not general anti-aging treatment.
Regulatory scope
U.S. label record for BLA020280. This does not confer authorization on other products using the ingredient name.
What remains unknown
Named-product label sections were expanded for pharmacokinetics, contraindications and selected handling or interaction details on September 7, 2026. This is not a complete trial-program appraisal or clinician sign-off. Other formulations, patient-specific decisions and other jurisdictions require separate assessment.
How it works
GENOTROPIN somatropin cartridges and MiniQuick devices
Consult the product label for pharmacology. A mechanism does not extend its approved indications.
Approved product exists
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
Reported adverse effects
- Critical illness, airway risks in Prader-Willi syndrome, neoplasms and glucose intolerance require clinical assessment.
Named U.S. presentation only; selected label sections.
Contraindications
- GENOTROPIN: acute critical illness after specified major surgery/trauma or respiratory failure; high-risk children with Prader-Willi syndrome; active malignancy; ingredient hypersensitivity; active proliferative/severe non-proliferative diabetic retinopathy; closed epiphyses when used for childhood growth promotion.
Approved product exists
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
Sources used for this snapshot
Claim-by-claim evidence
Adverseeffects
Critical illness, airway risks in Prader-Willi syndrome, neoplasms and glucose intolerance require clinical assessment.
Named U.S. presentation only; selected label sections.
Storage
GENOTROPIN cartridges: 2–8°C; after mixing refrigerate up to 28 days. MiniQuick: unopened may spend up to three months ≤25°C; after mixing refrigerate up to 24 hours, then single use. Protect from light; do not freeze.
Named U.S. presentation only; selected label sections.
Pharmacokinetics
GENOTROPIN: mean terminal half-life was about 0.4 hours after IV administration in normal adults and 3.0 hours after SC administration in adults with GH deficiency. Slower SC absorption explains the difference. Concentrations/formulations and patient populations are not interchangeable.
Named U.S. product only; label revision 20260804. Educational extraction, not complete clinical review.
Contraindications
GENOTROPIN: acute critical illness after specified major surgery/trauma or respiratory failure; high-risk children with Prader-Willi syndrome; active malignancy; ingredient hypersensitivity; active proliferative/severe non-proliferative diabetic retinopathy; closed epiphyses when used for childhood growth promotion.
Named U.S. product only; label revision 20260804. Educational extraction, not complete clinical review.
References
American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update. 2009.
PMID: 20228036
GENOTROPIN somatropin cartridges and MiniQuick devices. U.S. structured product label, effective 20260804. Selected sections only.
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.